Yiming Oncobiomedicine Technology

Yiming Oncobiomedicine is a clinical-stage biotechnology company based in Guangzhou, China, specializing in the discovery and development of innovative cancer therapies. The company focuses on immunotherapy and targeted therapies, leveraging a proprietary platform for high-throughput antibody screening to identify novel drug candidates. Its pipeline includes several monoclonal antibodies and small molecule inhibitors targeting well-validated pathways such as PD-1/PD-L1 and VEGF. Yiming Oncobiomedicine aims to address unmet medical needs in oncology by developing more effective and affordable treatments for prevalent cancers like lung and liver cancer. The company is actively advancing multiple programs through various stages of clinical trials in the Chinese market.